Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breakthrough Therapies: Failed Study Won’t Automatically Lead To Rescinded Designation

Executive Summary

The decision to maintain or revoke breakthrough therapy status when trial results do not appear to support the original designation will depend on the facts specific to a development program, the US FDA says in new draft guidance. Since 2012, the agency has granted 475 breakthrough therapy designation requests and rescinded 35 designations.

You may also be interested in...



Breakthrough Therapies: Another Drug’s Approval Should Not Lead To De Facto Rescission, Industry Says

Industry and patient advocacy groups urge the agency to consider a variety of factors in determining whether a drug’s breakthrough designation should be rescinded upon the approval of another product; draft guidance language on quality of clinical evidence to be considered in rescission decisions raises concerns specific to rare disease populations.

Half Of US FDA’s Breakthrough Therapy Designations Have Resulted In Approval

Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.

Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans

US FDA rescinds breakthrough designations for Tonix’ PTSD therapy Tonyma and Trevena’s novel pain drug Olinvo after clinical trial disappointments – and after identifying other regulatory pathways to market.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel